A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

NCT06190951 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

151

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: cemiplimab
DRUG: Fixed Dose Combination (FDC) cemiplimab+fianlimab
DRUG: Placebo

Sponsor

Regeneron Pharmaceuticals